Advertisement

Topics

FDA OKs 8-Week Mavyret for Hepatitis C

14:40 EDT 3 Aug 2017 | Medscape

Glecaprevir/pibrentasvir is the first HCV treatment of this duration approved for genotypes 1 through 6 in previously untreated adults without cirrhosis.
FDA Approvals

Original Article: FDA OKs 8-Week Mavyret for Hepatitis C

NEXT ARTICLE

More From BioPortfolio on "FDA OKs 8-Week Mavyret for Hepatitis C"

Quick Search
Advertisement